title: [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].
abstract: The lower urinary tract (LUT) is regulated by a complex neural network that is subject to supraspinal control. Neurological disorders, especially of the central nervous system (CNS), can rapidly lead to disruption of this control. Multiple sclerosis, Parkinson's disease, multiple system atrophy, and stroke are neurological disorders which quite frequently cause dysfunction of the LUT. With respect to the pathophysiology of bladder dysfunction in CNS diseases there are various hypotheses regarding the individual disorders: disturbances of neural communication between the frontal cortex and pontine micturition center, between the pontine micturition center and the lumbosacral parts of the spinal cord, and between the basal ganglia, thalamus, and anterior cingulate gyrus appear to play a pivotal role in the development of bladder dysfunction. The symptoms and urodynamic presentation of LUT dysfunction can vary considerably depending on the disease and disease progression and can change in the course of the disease. The incidence and prevalence of LUT dysfunctions rise with increasing progression of the underlying neurological disease.Various conservative, minimally invasive, and open surgical procedures are available to prevent harmful sequelae and to improve the quality of life of these patients. As yet, however, few data exist on most of the treatment options in cases of the above-mentioned CNS diseases. Intermittent self-catheterization and antimuscarinic medications are among the most important conservative treatment options. Injection of botulinum neurotoxin type A into the detrusor muscle and increasingly sacral or pudendal neuromodulation are among the most important minimally invasive treatment options. Surgical methods include reconstructive continent or incontinent urinary diversion.When planning therapy the patient's current needs and neurological limitations as well as possible disease progression must be taken into consideration. It is often advisable to consult with and enlist the cooperation of the attending neurologist when planning treatment.
authors.affiliation: Urologische Klinik, Marienhospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Widumer Straße 8, 44627 Herne, Deutschland. ulrich.mehnert@marienhospital-herne.de
authors.forename: U
authors.initials: U
authors.lastname: Mehnert
authors.forename: M
authors.initials: M
authors.lastname: Nehiba
mesh_terms: D001921:Brain / Q000503:physiopathology; D002493:Central Nervous System Diseases / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology*; D003430:Cross-Sectional Studies; D004599:Electric Stimulation Therapy; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology* / Q000628:therapy; D009103:Multiple Sclerosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D019578:Multiple System Atrophy / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D009434:Neural Pathways / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D013116:Spinal Cord / Q000503:physiopathology; D020521:Stroke / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome; D014521:Urethra / Q000294:innervation; D001743:Urinary Bladder / Q000294:innervation; D001750:Urinary Bladder, Neurogenic / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology* / Q000628:therapy; D014563:Urodynamics / Q000502:physiology